Methylnaltrexone
- Generic Name
- Methylnaltrexone
- Brand Names
- Relistor
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26NO4
- CAS Number
- 916055-93-1
- Unique Ingredient Identifier
- 0RK7M7IABE
- Background
Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
- Indication
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.
- Associated Conditions
- Opioid Induced Constipation (OIC)
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01366378
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01366365
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Tolerance and Pharmacokinetics Study of MNTX Tablets
- Conditions
- Normal Healthy Volunteers
- Interventions
- Drug: Oral placebo
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01366339
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01366326
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
- Conditions
- Normal Volunteers
- Interventions
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01366352
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 546
- Registration Number
- NCT01363323
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Tarrytown, New York, United States
Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Drexel University
- Registration Number
- NCT01360372
- Locations
- 🇺🇸
Cancer Treatment Center of America, Philadelphia, Pennsylvania, United States
🇺🇸Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
- Conditions
- Opioid-Induced Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 804
- Registration Number
- NCT01186770
- Locations
- 🇺🇸
PRA International, Raleigh, North Carolina, United States
🇺🇸PRA, Intl., Raleigh, North Carolina, United States
Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2011-03-31
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 42
- Registration Number
- NCT01117376
- Locations
- 🇮🇷
Nemazee Hospital, Shiraz, Fars, Iran, Islamic Republic of
Effect of Methylnaltrexone on GI Transit in Healthy Volunteers
- Conditions
- Gastric Motility Disorder
- Interventions
- Drug: Placebo + placebo
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 48
- Registration Number
- NCT01055704
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.